OEM Lecture Series: How Strategic Decision Makers Can Accelerate Outcomes of Biomarker Information Analysis
(Room Exhibit Hall Theater 2)
28 Jul 15
12:30 PM
-
12:50 PM
Information overload is a persistent problem for professionals interested in molecular biomarkers and is exacerbated by ‘single-use information culture’ within organizations. Please join us to discover how your organization can solve these challenges.
At Amplion, we see biomarkers as the key to delivering on the promise of personalized medicine. From drug research and discovery and companion diagnostic development to patient care, we understand that biomarkers will drive personalized care.
Researchers can now have an unprecedented view of the clinical biomarker landscape with every biomarker in an FDA-approved test or drug label, thousands of biomarkers in clinical trials, and with the recent inclusion of Laboratory Developed Tests (LDTs,) 30% more of the newest and most innovative clinical biomarkers are now normalized and readily accessible through the intuitive interface of BiomarkerBase™.